FDA Poised to Approve New Alzheimer's Drug
The U.S. Food and Drug Administration is expected to approve the experimental dementia drug Lecanemab as soon as this week, a move embraced by Alzheimer's disease researchers after trials showed it slowed the progression of the disease in some patients with mild cognitive impairment. The new potential therapy is also raising hopes that it could help those who are symptom-free but have brain changes -- detected by new blood tests -- that signal Alzheimer's. We'll talk about the latest advances in Alzheimer's research. Guests: Dr. Adam Boxer, endowed professor in memory and aging and professor…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.